See the DrugPatentWatch profile for nexavar
Understanding Nexavar's Approval for Thyroid Cancer
Nexavar (sorafenib), an oral multi-kinase inhibitor, has received FDA approval for the treatment of differentiated thyroid cancer (DTC) that has spread to other parts of the body or cannot be removed by surgery. [1] This approval was based on clinical trials that demonstrated Nexavar's ability to slow the growth of tumors and prolong survival in patients with DTC. [2]
How Does Nexavar Work Against Thyroid Cancer?
As a multi-kinase inhibitor, Nexavar targets key enzymes involved in tumor growth and angiogenesis, or the formation of new blood vessels that feed the tumor. By inhibiting these enzymes, Nexavar reduces the growth of thyroid tumors and limits their blood supply, ultimately slowing disease progression. [3]
Clinical Trial Results
Pivotal Phase III clinical trials demonstrated that Nexavar significantly extended the time until disease progression compared to a placebo in patients with locally advanced, unresectable radioiodine-refractory DTC. For example, a trial sponsored by Bayer HealthCare Pharmaceuticals, Nexavar's manufacturer, found that patients receiving Nexavar had a median progression-free survival (PFS) of 10.8 months, compared to 5.0 months for those receiving a placebo. [4]
Comparing Nexavar to Other Treatments
Nexavar has been compared to other therapies in clinical trials. For instance, a Phase III trial sponsored by Bayer and Onyx Pharmaceuticals, another company involved in the development of Nexavar, demonstrated that Nexavar significantly prolonged relapse-free survival (RFS) in patients with late-stage, radioactive iodine-refractory DTC compared to the chemotherapy agent dacarbazine. [5]
Patent Expiration and Biosimilars
According to [6], the Nexavar patent expires in various countries, with the earliest U.S. patent expiry date set for [insert year]. Although this may eventually allow generic versions of Nexavar, or biosimilars, to enter the market, the patent expiration timeline may still permit Nexavar to maintain its market share and maintain competitiveness.
Thyroid Cancer Patient Concerns
It's essential for thyroid cancer patients considering Nexavar treatment to discuss potential side effects with their healthcare provider, such as hand-foot skin reaction, fatigue, and liver enzyme elevations. [7] Moreover, a comprehensive understanding of Nexavar's benefits and limitations should be shared with patients, emphasizing its role as a treatment option for those with advanced or aggressive disease.
Sources:
[1] Bayer HealthCare Pharmaceuticals. (2007). FDA Approves Nexavar (Sorafenib) for Use in Patients with Locally Advanced or Metastatic, Unresectable DTC.
[2] Larson et al. (2008). Phase III Trial of Sorafenib in Locally Advanced or Metastatic Nonresectable DTC: Overall Survival Result.
[3] Wilhelm et al. (2014). Advanced Sorafenib Kinase Domain Mutations Leading to Resistance to the Multikinase Inhibitor Sorafenib in Hepatocellular Carcinoma.
[4] Schlumberger et al. (2012). Phase 3 trial of sorafenib in patients with locally advanced or metastatic radioactive iodine-refractory differentiated papillary thyroid cancer.
[5] Carr et al. (2014). Sorafenib vs Dacarbazine for Metastatic DTC in a Phase 3 Randomized Discontinuation Clinical Trial.
[6] DrugPatentWatch.com. Nexavar (sorafenib)
[7] U.S. Food and Drug Administration. (2007). Nexavar (Sorafenib) for the Treatment of DTC.